Suppr超能文献

地尔硫䓬在控制快速心室率心房颤动管理中的给药策略

Diltiazem Dosing Strategies in the Management of Atrial Fibrillation With Rapid Ventricular Rate.

作者信息

Bishop James, Akram Ghufraan

机构信息

Emergency Medicine, Ascension Providence Hospital-Southfield, Southfield, USA.

Emergency Medicine, Michigan State University College of Human Medicine, East Lansing, USA.

出版信息

Cureus. 2021 Oct 16;13(10):e18829. doi: 10.7759/cureus.18829. eCollection 2021 Oct.

Abstract

Introduction Diltiazem is commonly used for the management of atrial fibrillation (AFIB) with rapid ventricular rate (RVR) in the emergency department (ED). Conflicting studies comparing the efficacy of diltiazem have led to various dosing strategies. The objective of this study was to investigate diltiazem administration in a community ED and determine the effect of varying doses on heart rate (HR) control, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Methods This is a retrospective, single-center study of adult patients treated with diltiazem for AFIB-RVR in the ED between January 1 and December 31, 2019. Inclusion criteria included pretreatment HR > 120 beats per minute (bpm). Patients were administered diltiazem at the discretion of the ED physician. Primary endpoint was time to achieve HR < 100 bpm after diltiazem. Secondary endpoints included mean weight-based dose of diltiazem, percentage of patients achieving HR < 100 bpm within 240 minutes of diltiazem, nadir SBP and nadir DBP. Results Ninety-nine patients were included in the study. Seventy-two percent of patients received ≤ 10 mg diltiazem bolus. Mean weight-based dose of diltiazem bolus was 0.13 mg/kg. Mean time to achieve HR < 100 bpm was 270 minutes for the entire cohort. Patients treated with ≥ 0.13 mg/kg diltiazem achieved an HR < 100 bpm at a mean time of 169 minutes compared to 318 minutes for < 0.13 mg/kg (p = 0.0107). HR control was achieved in 61% of patients who received ≥ 0.13 mg/kg compared to 36% of patients who received < 0.13 mg/kg diltiazem (p = 0.0213). No patients discontinued diltiazem for hypotension or bradycardia. The lowest recorded SBP and DBP within 240 minutes of diltiazem were 90 mmHg and 47 mmHg, respectively. There was no significant difference in the lowest SBP and DBP for patients who received < 0.13 mg/kg compared to ≥ 0.13 mg/mg diltiazem. Conclusion The majority of patients with AFIB RVR received a 10 mg non-weight-based diltiazem bolus dose in the ED. Diltiazem bolus dosing ≥ 0.13 mg/kg was associated with significantly improved times to achieve HR control compared to < 0.13 mg/kg and was not associated with hypotension or bradycardia.

摘要

引言

地尔硫䓬常用于急诊科(ED)对伴有快速心室率(RVR)的心房颤动(AFIB)的治疗。比较地尔硫䓬疗效的研究结果相互矛盾,导致了各种给药策略。本研究的目的是调查社区急诊科使用地尔硫䓬的情况,并确定不同剂量对心率(HR)控制、收缩压(SBP)和舒张压(DBP)的影响。

方法

这是一项回顾性单中心研究,研究对象为2019年1月1日至12月31日期间在急诊科接受地尔硫䓬治疗AFIB-RVR的成年患者。纳入标准包括治疗前心率>120次/分钟(bpm)。地尔硫䓬由急诊科医生酌情给药。主要终点是地尔硫䓬给药后心率降至<100 bpm的时间。次要终点包括基于体重的地尔硫䓬平均剂量、地尔硫䓬给药后240分钟内心率降至<100 bpm的患者百分比、最低收缩压和最低舒张压。

结果

99例患者纳入本研究。72%的患者接受了≤10 mg的地尔硫䓬推注。基于体重的地尔硫䓬推注平均剂量为0.13 mg/kg。整个队列达到心率<100 bpm的平均时间为270分钟。接受≥0.13 mg/kg地尔硫䓬治疗的患者达到心率<100 bpm的平均时间为169分钟,而接受<0.13 mg/kg地尔硫䓬治疗的患者为318分钟(p = 0.0107)。接受≥0.13 mg/kg地尔硫䓬治疗的患者中有61%实现了心率控制,而接受<0.13 mg/kg地尔硫䓬治疗的患者中这一比例为36%(p = 0.0213)。没有患者因低血压或心动过缓而停用 地尔硫䓬。地尔硫䓬给药后24小时内记录到的最低收缩压和舒张压分别为90 mmHg和47 mmHg。接受<0.13 mg/kg地尔硫䓬治疗的患者与接受≥0.13 mg/kg地尔硫䓬治疗的患者相比,最低收缩压和舒张压没有显著差异。

结论

大多数伴有AFIB-RVR的患者在急诊科接受了10 mg非体重基础的地尔硫䓬推注剂量。与<0.13 mg/kg相比,地尔硫䓬推注剂量≥0.13 mg/kg与显著改善心率控制时间相关,且与低血压或心动过缓无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600b/8592802/022a7d7063da/cureus-0013-00000018829-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验